MCMedicalCodingSoftware
Free trial
XW043NA

XW043NA — Introduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Tarlatamab-dlle in Central Vein, Perc, New Tech 10

How XW043NA is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective — the verb of the procedure
  4. 4Body partThe specific site
  5. 3ApproachHow the site was reached
  6. NDeviceWhat was left in place, if anything
  7. AQualifierA further distinction where one applies

Codes near XW043NA

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XW043J7Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043K7Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043K9Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
  • XW043L6Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043L7Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043MAIntroduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043N7Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043NAIntroduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043P9Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
  • XW043PBIntroduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW043Q5Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043Q9Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
  • XW043QBIntroduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW043R9Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9
  • XW043RBIntroduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW043S5Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
ICD-10-PCSFY2026